Navigation Links
Novel Therapy Tested in Mice Could Chase Away Cat Allergies

A molecule designed to block cat allergies successfully prevented allergic reactions in laboratory mice, as well as in human cells in a test tube, University of California, Los Angeles (UCLA) researchers report in the April issue of Nature Medicine, available online now. In the future, the investigators say, these promising results could lead to a new therapy not only for human cat allergies, but also possibly for severe food allergies such as those to peanuts.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, funded the research. “This novel approach to treating cat allergies is encouraging news for millions of cat-allergic Americans. Moreover, these results provide proof-of-concept for using this approach to develop therapies to prevent deadly food allergy reactions as well,?says NIAID Director Anthony S. Fauci, M.D.

The injectable treatment puts a brake on the release of a key chemical from cells involved in cat allergy reactions. That chemical, histamine, brings on allergy symptoms such as sneezing, wheezing, itching, watery eyes, and sometimes asthma. When a cat-allergic person touches or inhales a protein found in cat saliva or dander (small scales from its skin or hair), key immune system cells respond by spewing out histamine. Allergy experts estimate that 14 percent of children 6 to 19 years old are allergic to cats.

The treatment comprises a molecule that loosely tethers a feline and a human protein together. The feline end is the notorious protein (called Fel d1) found in cat dander and saliva that causes so much misery in allergy sufferers. On the other end sits a piece of human antibody (called IgG Fcg1) that docks to a cell receptor that can be recruited to stop allergic reactions.

The investigators named the chimeric molecule GFD, or gamma Feline domesticus, for its human and feline parts, explains principal investigator Andrew Saxon, M.D., of UCLA. The cat alle rgen end of GFD binds to antibodies on the surface of the cell. The human end of GFD links to a different cell surface protein (called FcgRIIB) that interrupts the allergic response.

Dr. Saxon and his colleagues first tested GFD in blood donated by people allergic to cats. They cultured blood cells with either GFD or with a purified human antibody as a control. Then they added the cat protein that triggers allergic reactions to all the blood cell cultures.

“We measured more than 90 percent less histamine in the cultures with GFD,?says Dr. Saxon. “Those results suggested that GFD successfully prevented the immune cells from reacting to cat allergen. The next step was to test GFD in mice that we had made allergic to the allergenic protein found in cat saliva and dander.?/p>

The researchers tested GFD in two different types of allergic mice. One set was genetically engineered to have human cat-allergy cell receptors. These mice were “passively allergic?to cats: they would react to cat protein only after the scientists first injected them with human allergic antibodies to cats. When these mice were then injected with cat allergen, GFD blocked the allergic reaction involving the human cell receptors, an indication that it might also work in people.

Scientists made another set of mice allergic to cats by injecting them with cat protein and an immune system booster. These mice became “actively allergic?to cats: their reactions to cat allergen would be comparable to reactions in a cat-allergic person. Scientists injected some of these mice with GFD, and then injected cat allergen into the windpipes of all the mice, including a control group that was not allergic to cats. GFD damped asthma-like and other allergic reactions in the cat-allergic mice: reactions in the mice that received GFD were similar to the control group mice that were not allergic to cats.

The molecule has the potential to prevent allergic reactions long after injections cease, Dr. Saxon says. However, further research and clinical testing would be required before it might be used in humans. He also is interested in applying this approach to develop a preventive treatment for serious food allergies.


'"/>

Source:NIH


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Discovery Could Lead To Novel Approaches In HIV Treatment
6. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
7. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
8. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
9. Novel live reporting system to track cells
10. Field of beams - Novel system uses polarized light pulses to reveal crop health
11. Novel compounds show promise as safer, more potent insecticides
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 2017   VWR (NASDAQ: VWR), ... and service solutions to laboratory and production ... EPL Archives, Inc., an international biorepository services ... regulated product research, development and commercialization lifecycle ... ancillary services. EPL Archives is widely recognized ...
(Date:3/22/2017)... ... 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the ... “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ ... and Therapy Act, Okyanos maintains a mission to help “no-option” patients and those ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO ... Executive Officer Forum on March 23-24 in San Diego. The event is a ... diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in the ...
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
Breaking Biology Technology: